<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400309</url>
  </required_header>
  <id_info>
    <org_study_id>F06-Td5I-301</org_study_id>
    <nct_id>NCT00400309</nct_id>
  </id_info>
  <brief_title>Safety of REPEVAX® Given One Month After REVAXIS®</brief_title>
  <official_title>A Double Blind, Controlled, Randomised, Clinical Study to Assess the Safety of Repevax® Administered One Month After Revaxis® or Placebo to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  To describe the safety profile of a Tetanus, Diphtheria, Poliomyelitis and Pertussis&#xD;
           vaccine (REPEVAX®) when administered as a pertussis booster 1 month after a Tetanus,&#xD;
           Diphtheria, Poliomyelitis vaccine (REVAXIS®) as compared to the safety profile of&#xD;
           REPEVAX® administered one month after Placebo.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To describe the safety of Td-IPV vaccine (REVAXIS®) or Placebo administered to healthy&#xD;
           adults.&#xD;
&#xD;
        -  To describe the safety of TdaP-IPV vaccine (REPEVAX®) administered one month after&#xD;
           Td-IPV vaccine (REVAXIS®) or one month after Placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>injection sites reactions and systemic events during the 7 day-safety period post-vaccination with TdaP-IPV vaccine.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>injection-site adverse reactions and systemic adverse events during the 14 day-safety period post-vaccination with Td-IPV vaccine, TdaP-IPV vaccine and placebo and serious adverse events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Healthy Adult</condition>
  <arm_group>
    <arm_group_label>REPEVAX® after REVAXIS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REPEVAX® after Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REPEVAX® after REVAXIS®</intervention_name>
    <description>Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)</description>
    <arm_group_label>REPEVAX® after REVAXIS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REPEVAX® after Placebo</intervention_name>
    <description>Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo</description>
    <arm_group_label>REPEVAX® after Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult, with vaccination history (by written evidence) of a minimum of 5 doses&#xD;
             of a tetanus, diphtheria and poliomyelitis containing vaccine as recommended in the&#xD;
             French vaccination calendar at 18 years old, and a maximum of 8 doses.&#xD;
&#xD;
          -  Last dose of a tetanus and/or diphtheria and/or poliomyelitis containing vaccine&#xD;
             administered either alone or in combination at least 5 years prior to the&#xD;
             administration of the first study vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior known hypersensitivity reaction to any diphtheria and/or tetanus and/or&#xD;
             poliomyelitis and/or pertussis containing vaccine&#xD;
&#xD;
          -  Any current (≤ 3 days) significant underlying disease or acute febrile illness (oral&#xD;
             temperature ≥37.5°C)&#xD;
&#xD;
          -  Known immunological deficiency&#xD;
&#xD;
          -  Known malignant disease&#xD;
&#xD;
          -  Known neurological disorder&#xD;
&#xD;
          -  Any long-term (≥ 14 days) non steroid anti-inflammatory therapy given daily within the&#xD;
             previous 30 days&#xD;
&#xD;
          -  Known history of severe thrombocytopenia or any coagulation disorder that would&#xD;
             contraindicate intramuscular injection&#xD;
&#xD;
          -  Any previous (≤ 90 days) administration of blood-derived products or immunoglobulins&#xD;
             or scheduled to be administered through Visit 3&#xD;
&#xD;
          -  Any recent administration (≤ 30 days) of a vaccine or scheduled vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

